Biosimilars

COVID-19

Cataract Surgery

Cataract

Cataract Therapeutics

NeuroOp Guru

The Residency Report

Clinical Diagnosis

Cornea

Dry Eye Awareness

Dry Eye

Gene Therapy

Geographic Atrophy

IOL Advances

Imaging

Glaucoma Awareness

Glaucoma Insights

Therapeutic Glaucoma

Interventional Glaucoma

Ocular Allergy

Ocular Surface Disease

Optic Relief

Optometry

Pediatrics

Pharmacy

Indispensable

Practice Management

Presbyopia

Ptosis

Refractive Surgery

Refractive

Retina

Surgery

Technology

Therapeutics

Understanding Antibiotic Resistance

Workplace

News

All News

Contributors

Money Matters

Media

All Videos

Expert Interviews

Medical World News

Podcasts

Case Based Roundtable Series

Case of the Quarter

EyeView

Grand Rounds

Insights

Rapid Readout

Viewpoints

What’s Your WhEYE?

Conferences

Conference Coverage

Conference Listing

Events

Publications

Digital Edition

Europe Ophthalmology Times

Modern Retina

Supplements and Featured Publications

Partners

Subscribe

Resources

Job Board

Videos

At ARVO 2025, in Salt Lake City, Utah, Xiaolin Wang, MS, talked about her presentation on in vivo imaging of retinal pigment epithelium metabolic function in AMD.

ARVO 2025: In vivo imaging of RPE metabolic function in AMD

Articles

Susvimo is the first and only FDA-approved, continuous delivery treatment shown to maintain vision in people with DR with just one refill every 9 months

Genentech’s Susvimo receives new FDA indication for diabetic retinopathy

Join global experts at the 2025 International SPECTRALIS Symposium in Heidelberg, exploring innovations in ophthalmology and space-related ocular health.

NASA astronauts to keynote 2025 Internatioal SPECTRALIS Symposium in Heidelberg

At ARVO 2025, in Salt Lake City, Utah, Noemi Guemes-Villahoz, MD, PhD, talked about 12-month results of vision-related quality of life in myopic children using combination treatment with atropine and DIMS (Defocus Incorporated Multiple Segments) spectacle lenses.

ARVO 2025: 12-month results  in myopic children using combination treatment of atropine and DIMS spectacle lenses

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.

About

Advertise

Privacy

Editorial Info

Editorial Board

Terms and Conditions

Contact Us

Do Not Sell My Personal Information

Ophthalmology Times - Ophthalmology news, articles, and events

Facebook

Instagram

LinkedIn

Spotlight

Clinical

Glaucoma

View

Irvine, CA-In anticipation of the initial public offering (IPO) of its common stock, IntraLase Corp. has filed a registration statement with the Securities and Exchange Commission.

IntraLase prepares for $92 million IPO

IntraLase prepares for $92 million IPO

Newsletter